title: Chronic inflammation as predictor of 1-year hospitalization and mortality in elderly population.
abstract: BACKGROUND
  Systemic low-grade inflammation is thought to be associated with an increased risk of adverse clinical outcomes in elderly population. We tested this notion with the goal of identifying useful potential biomarkers of 1-year hospitalization and mortality in the elderly population.
  
  
  METHODS
  A total of 120 institutionalized older subjects were enrolled as participants in this study, including 90 women and 30 men (ranging in age from 68 to 105 years), selected from Santa Teresa nursing home (Oviedo, Spain). We studied functional status, morbidity, socio-demographic characteristics and several inflammation and inflammation-related markers.
  
  
  RESULTS
  The study included 95 non-hospitalized participants and 23 participants with at least one hospitalization during 1 year (19% of subjects). The study also included 100 survivors and 19 participants who died during the 1-year study (16% of subjects). In logistic regression models adjusted by age, sex, anti-inflammatory drug use and morbid conditions, high levels of interleukin 1 receptor antagonist (IL-1ra) and red blood cell distribution width (RDW) were associated with hospitalization and death at 1 year. Elevated levels of tumour necrosis factor α (TNF-α) were also associated with an increased risk of death at 1 year after adjusting for the same potential confounders. Multivariate logistic regression models showed that elevated serum levels of IL-1ra were intimately associated with 1-year subsequent hospitalization and mortality in aged subjects after adjusting for age, sex, anti-inflammatory drug use and morbid conditions.
  
  
  CONCLUSIONS
  Current data suggest that IL-1ra is a predictor of 1-year hospitalization and mortality in the elderly population.
authors.affiliation: Department of Morphology and Cellular Biology, Cellular Biology Area, Faculty of Medicine, University of Oviedo, Oviedo, Spain. ddgonzalo@hotmail.com
authors.forename: David
authors.initials: D
authors.lastname: de Gonzalo-Calvo
authors.forename: Beatriz
authors.initials: B
authors.lastname: de Luxán-Delgado
authors.forename: Pablo
authors.initials: P
authors.lastname: Martínez-Camblor
authors.forename: Susana
authors.initials: S
authors.lastname: Rodríguez-González
authors.forename: Marina
authors.initials: M
authors.lastname: García-Macia
authors.forename: Francisco M
authors.initials: FM
authors.lastname: Suárez
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Solano
authors.forename: María J
authors.initials: MJ
authors.lastname: Rodríguez-Colunga
authors.forename: Ana
authors.initials: A
authors.lastname: Coto-Montes
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D004912:Erythrocytes / Q000502:physiology; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000453:epidemiology* / Q000401:mortality; D053590:Interleukin 1 Receptor Antagonist Protein / Q000097:blood*; D008297:Male; D011379:Prognosis; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D015415:Biomarkers; D053590:Interleukin 1 Receptor Antagonist Protein; D014409:Tumor Necrosis Factor-alpha